Trial Profile

Randomized Controlled Trial of Infliximab (Remicade) Induction Therapy for Deceased Donor Kidney Transplant Recipients (CTOT-19)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 14 Feb 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Infliximab (Primary) ; Antithymocyte globulin; Diphenhydramine; Loratadine; Methylprednisolone; Mycophenolate mofetil; Paracetamol; Prednisone; Tacrolimus
Indications Inflammation; Renal transplant rejection
Focus Therapeutic Use
Acronyms CTOT-19

Most Recent Events

01 Jan 2023 Primary endpoint has not been met according to results published in the Journal of the American Society of Nephrology
01 Jan 2023 Results assessing Efficacy of Infliximab Induction and Increases BK Virus Infection in Deceased Donor Kidney Transplant Recipientspublished in the Journal of the American Society of Nephrology
10 Aug 2021 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com